SequelSEC

BIOTRICITY INC. BTCY

Surgical & Medical Instruments & Apparatus · CIK 0001630113 · Fiscal year ends 0331

AnnualQuarterlyTTM
Revenue
$16.40M
Fiscal year ended 2026-06-30
Operating income
$1.57M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$13.50MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-09-30
Float per share$0.67Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-09-30, not today, and each multiple below it uses the figures for the fiscal year ending 2026-03-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue0.2%3th
Current ratio0.16x5th
Gross margin80.9%88th
Operating margin10.6%80th
Net margin-15.0%57th
Revenue YoY growth16.0%56th
R&D / revenue17.3%54th

BIOTRICITY INC. (BTCY) reported revenue of $16.40M and net income of -$2.69M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BIOTRICITY INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

BIOTRICITY INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$16.40M
Cost of revenue$3.04M
Gross profit$13.36M
Operating income$1.57M
Net income-$2.69M
Research & development$2.74M
Weighted-average diluted sharesUnavailable
Pretax income-$2.69M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$9.05M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

BIOTRICITY INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$466.50K
Total assets$6.02M
Current assets$5.60M
Total liabilities$39.72M
Current liabilities$37.34M
Total equity incl. NCI-$35.41M
Temporary (mezzanine) equity$1.71M
Inventory$1.43M
Accounts receivable$2.40M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

BIOTRICITY INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$161.66K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow-$68.90K
Net change in cashUnavailable
Stock-based compensation$359.67K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

BIOTRICITY INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin81.5%
Operating margin9.6%
FCF marginUnavailable
SBC / revenue2.2%
Current ratio0.15x
Revenue YoY growth13.4%
Net margin-16.4%
R&D / revenue16.7%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BTCY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-K · Filed 2026-07-14View SEC filing
10-Q · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-K/A · Filed 2025-07-18View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.